Rheumatoid Arthritis
Conditions
Keywords
Rheumatoid Arthritis, glucocorticoid, intraarticular injection, arthritis
Brief summary
The purpose of this study is to compare the efficacy and safety of intra-articular glucocorticoid injection to its systemic use for treatment of knee synovitis in patients with Rheumatoid Arthritis
Detailed description
A randomized double-blind controlled study was conducted including 60 patients with RA. Patients were randomized to receive either a single intra-articular knee injection with triamcinolone hexacetonide 60 mg and xylocaine chloride 2% (1 mL) associated to a single intramuscular injection of 1 mL of xylocaine chloride 2% (IAI group) or 1 mL of xylocaine chloride 2% by intra-articular injection and a intramuscular injection of triamcinolone acetonide 60 mg and xylocaine chloride 2% (1 mL) (IM group). Evaluations were performed at baseline and 1, 4, 8 and 12 weeks post-intervention. The following instruments were used: the ACR 20%, 50 and 70% improvement criteria; VAS for knee morning stiffness, pain and edema; knee circumference and goniometry; Likert's scale of improvement (IVAS); daily use of oral glucocorticoid and NSAIDs, blood pressure and adverse effects.
Interventions
Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
Sponsors
Federal University of São Paulo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Rheumatoid Arthritis diagnosed for more than 6 months * 18 and 65 years * Functional class II or III according to the ACR criteria * VAS for knee pain higher than 5 * Use of stable doses of oral corticosteroid for the last 30 days * Use of stable doses of DMARDs for the last 3 months * Active synovitis at least in one knee for at least the 30 days
Exclusion criteria
* Non-controlled diabetes mellitus or hypertension * Bacterial infection of any site * Blood coagulation disorders * Skin lesion on the affected knee * History of previous surgical procedure in the knee * Use of intra-muscular glucocorticoid in the last 30 days * Intra-articular injection in the last 3 months * Knee injection in the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS for knee pain | 12 weeks post intervention |
Secondary
| Measure | Time frame |
|---|---|
| side and adverse effects, safety | 12 weeks post intervention |
Countries
Brazil
Outcome results
None listed